$AHR
American Healthcare REIT, Inc. Stock $ahr

$ahr Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000163297023000058 Filed on May 15, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$408.6M	$319.0M
YoY Change	28.11%	742.93%
Cost Of Revenue	$370.1M	$287.2M
YoY Change	28.9%	17.14%
Gross Profit	$38.48M	$31.81M
YoY Change	20.97%	-115.35%
Gross Profit Margin	9.42%	9.97%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$44.67M	$42.31M
YoY Change	5.58%	64.49%
% of Gross Profit	116.07%	132.99%
Operating Expenses
YoY Change
Operating Profit	$66.89M	$73.68M
YoY Change	-9.23%	93.49%
Interest Expense	$39.01M	$23.33M
YoY Change	67.25%	14.53%
% of Operating Profit	58.33%	31.66%
Other Income/Expense, Net	-$36.30M	-$20.81M
YoY Change	74.44%	4.24%
Pretax Income	-$27.47M	-$729.0K
YoY Change	3668.45%	-95.47%
Income Tax	$143.0K	$168.0K
% Of Pretax Income
Net Earnings	-$25.87M	-$2.956M
YoY Change	775.24%	-75.05%
Net Earnings / Revenue	-6.33%	-0.93%
Basic Earnings Per Share	-$0.39	-$0.01
Diluted Earnings Per Share	-$0.39	-$0.01
COMMON SHARES
Basic Shares Outstanding	66.03M shares	262.5M shares
Diluted Shares Outstanding	66.03M shares	262.5M shares

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$41.35M	$75.12M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$19.05M	$18.09M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill	$234.9M	$211.7M
YoY Change	10.97%
Intangibles	$219.3M	$241.1M
YoY Change	-9.07%	302.53%
Long-Term Investments	$15.40M	$22.73M
YoY Change	-32.24%	-50.32%
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$4.748B	$4.556B
YoY Change	4.2%	319.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities
Total Liabilities	$3.161B	$2.750B
YoY Change	14.93%	406.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.181B	-$980.6M
YoY Change	20.41%	398.19%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.364B	$1.557B
YoY Change
Total Liabilities & Shareholders Equity	$4.748B	$4.556B
YoY Change	4.2%	319.29%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$25.87M	-$2.956M
YoY Change	775.24%	-75.05%
Depreciation, Depletion And Amortization	$44.67M	$42.31M
YoY Change	5.58%	64.49%
Cash From Operating Activities	$23.86M	$22.36M
YoY Change	6.72%	-525.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions	$335.0K	$0.00
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$33.32M	-$27.37M
YoY Change	21.75%	-74.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$78.00K	$4.134M
YoY Change	-98.11%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$14.30M	-$1.307M
YoY Change	994.11%	-101.46%
NET CHANGE
Cash From Operating Activities	$23.86M	$22.36M
Cash From Investing Activities	-$33.32M	-$27.37M
Cash From Financing Activities	-$14.30M	-$1.307M
Net Change In Cash	-$23.76M	-$6.314M
YoY Change	276.26%	-71.93%
FREE CASH FLOW
Cash From Operating Activities	$23.86M	$22.36M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92612
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001632970
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-55775
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	AMERICAN HEALTHCARE REIT, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MD
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2887436
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	18191 Von Karman Avenue
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine
CY2023Q1	dei	City Area Code CityAreaCode	949
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	270-9200
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	3568117000	usd
CY2022Q4	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	3581609000	usd
CY2023Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	83955000	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	83000000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41346000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65052000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	46883000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	46854000	usd
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	143740000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	137501000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	219279000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	236283000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	234942000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	231611000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	270939000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	276342000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	138480000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	128446000	usd
CY2023Q1	us-gaap	Assets Assets	4747681000	usd
CY2022Q4	us-gaap	Assets Assets	4786698000	usd
CY2023Q1	us-gaap	Secured Debt SecuredDebt	1233745000	usd
CY2022Q4	us-gaap	Secured Debt SecuredDebt	1229847000	usd
CY2023Q1	us-gaap	Line Of Credit LineOfCredit	1313222000	usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	1281794000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	231469000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	243831000	usd
CY2023Q1	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	10429000	usd
CY2022Q4	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	10837000	usd
CY2023Q1	gahr	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Financing Obligations BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancingObligations	47684000	usd
CY2022Q4	gahr	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Financing Obligations BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancingObligations	48406000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	268587000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	273075000	usd
CY2023Q1	gahr	Security Deposits Prepaid Rentand Other Liabilities SecurityDepositsPrepaidRentandOtherLiabilities	55672000	usd
CY2022Q4	gahr	Security Deposits Prepaid Rentand Other Liabilities SecurityDepositsPrepaidRentandOtherLiabilities	49545000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	3160808000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3137335000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	59884000	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	81598000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2546299000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2540424000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1180741000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1138304000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2568000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2690000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1363651000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1400091000	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	163338000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	167674000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1526989000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1567765000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4747681000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4786698000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	408630000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	318974000	usd
CY2023Q1	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	43596000	usd
CY2022Q1	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	51943000	usd
CY2023Q1	gahr	Government Grant Income From Cares Act GovernmentGrantIncomeFromCARESAct	0	usd
CY2022Q1	gahr	Government Grant Income From Cares Act GovernmentGrantIncomeFromCARESAct	5214000	usd
CY2023Q1	gahr	Revenuesand Government Grant Income From Cares Act RevenuesandGovernmentGrantIncomeFromCARESAct	452226000	usd
CY2022Q1	gahr	Revenuesand Government Grant Income From Cares Act RevenuesandGovernmentGrantIncomeFromCARESAct	376131000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	370146000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	287160000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	15195000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	15287000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13053000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11119000	usd
CY2023Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	332000	usd
CY2022Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	173000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	44670000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42311000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	443396000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	356050000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	39011000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	23325000	usd
CY2023Q1	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-195000	usd
CY2022Q1	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	500000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	143000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	168000	usd
CY2023Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	-132000	usd
CY2022Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	756000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-306000	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1386000	usd
CY2023Q1	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	726000	usd
CY2022Q1	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	0	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1008000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1387000	usd
CY2023Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1608000	usd
CY2022Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1260000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-36302000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20810000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27472000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-729000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-27615000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-897000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1743000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2059000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25872000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2956000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66026173	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66026173	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65629204	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65629204	shares
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-27615000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-897000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	122000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-194000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	122000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-194000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-27493000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1091000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1743000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	2059000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25750000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3150000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1567765000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1051000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	78000	usd
CY2023Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	3102000	usd
CY2023Q1	gahr	Reclassificationof Noncontrolling Interest ReclassificationofNoncontrollingInterest	-21000	usd
CY2023Q1	gahr	Adjustments To Additional Paid In Capital Adjustment To Redeemable Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalAdjustmentToRedeemableNoncontrollingInterests	-5043000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.25
CY2023Q1	us-gaap	Dividends Common Stock DividendsCommonStock	16565000	usd
CY2023Q1	gahr	Net Income Lossincluding Portion Attributableto Noncontrolling Interest Excluding Preferred Stock Dividend NetIncomeLossincludingPortionAttributabletoNoncontrollingInterestExcludingPreferredStockDividend	-27247000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	122000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1526989000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1756846000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	11304000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	811000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21000	usd
CY2022Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	4134000	usd
CY2022Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	3515000	usd
CY2022Q1	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	0	usd
CY2022Q1	gahr	Reclassificationof Noncontrolling Interest ReclassificationofNoncontrollingInterest	-21000	usd
CY2022Q1	gahr	Adjustments To Additional Paid In Capital Adjustment To Redeemable Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalAdjustmentToRedeemableNoncontrollingInterests	2856000	usd
CY2022Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.40
CY2022Q1	us-gaap	Dividends Common Stock DividendsCommonStock	26354000	usd
CY2022Q1	gahr	Net Income Lossincluding Portion Attributableto Noncontrolling Interest Excluding Preferred Stock Dividend NetIncomeLossincludingPortionAttributabletoNoncontrollingInterestExcludingPreferredStockDividend	-1084000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-194000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1730821000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-368000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	187000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-27615000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-897000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	44670000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	42311000	usd
CY2023Q1	gahr	Other Amortization OtherAmortization	20370000	usd
CY2022Q1	gahr	Other Amortization OtherAmortization	6166000	usd
CY2023Q1	us-gaap	Straight Line Rent Adjustments StraightLineRentAdjustments	-1090000	usd
CY2022Q1	us-gaap	Straight Line Rent Adjustments StraightLineRentAdjustments	-1695000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1072000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	779000	usd
CY2023Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	-132000	usd
CY2022Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	756000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-306000	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1386000	usd
CY2023Q1	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	726000	usd
CY2022Q1	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	0	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1063000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1335000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4591000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Financial Instruments Used In Operating Activities IncreaseDecreaseInOtherFinancialInstrumentsUsedInOperatingActivities	-195000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Financial Instruments Used In Operating Activities IncreaseDecreaseInOtherFinancialInstrumentsUsedInOperatingActivities	500000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	7119000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	8300000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3489000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1432000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1790000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7878000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-184000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	9328000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4602000	usd
CY2023Q1	gahr	Increase Decrease In Security Deposits Prepaid Rent And Other Liabilities IncreaseDecreaseInSecurityDepositsPrepaidRentAndOtherLiabilities	-5757000	usd
CY2022Q1	gahr	Increase Decrease In Security Deposits Prepaid Rent And Other Liabilities IncreaseDecreaseInSecurityDepositsPrepaidRentAndOtherLiabilities	5192000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	23862000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	22360000	usd
CY2023Q1	gahr	Payments To Develop Real Estate Assets And Payments For Capital Expenditures PaymentsToDevelopRealEstateAssetsAndPaymentsForCapitalExpenditures	21500000	usd
CY2022Q1	gahr	Payments To Develop Real Estate Assets And Payments For Capital Expenditures PaymentsToDevelopRealEstateAssetsAndPaymentsForCapitalExpenditures	20856000	usd
CY2023Q1	us-gaap	Payments To Acquire Real Estate PaymentsToAcquireRealEstate	11680000	usd
CY2022Q1	us-gaap	Payments To Acquire Real Estate PaymentsToAcquireRealEstate	19878000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	335000	usd
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Real Estate Heldforinvestment ProceedsFromSaleOfRealEstateHeldforinvestment	6901000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Real Estate Heldforinvestment ProceedsFromSaleOfRealEstateHeldforinvestment	14074000	usd
CY2023Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	6000000	usd
CY2022Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	200000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Deposits On Real Estate Acquisitions PaymentsForProceedsFromDepositsOnRealEstateAcquisitions	705000	usd
CY2022Q1	us-gaap	Payments For Proceeds From Deposits On Real Estate Acquisitions PaymentsForProceedsFromDepositsOnRealEstateAcquisitions	507000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33319000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27367000	usd
CY2023Q1	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	7700000	usd
CY2022Q1	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	22489000	usd
CY2023Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	5122000	usd
CY2022Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	4538000	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	113600000	usd
CY2022Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	941400000	usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	82100000	usd
CY2022Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	928900000	usd
CY2023Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1048000	usd
CY2022Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4796000	usd
CY2023Q1	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
CY2022Q1	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2790000	usd
CY2023Q1	gahr	Payments On Financing Obligations PaymentsOnFinancingObligations	733000	usd
CY2022Q1	gahr	Payments On Financing Obligations PaymentsOnFinancingObligations	787000	usd
CY2023Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	26492000	usd
CY2022Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	15010000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	78000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4134000	usd
CY2023Q1	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	3516000	usd
CY2022Q1	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	3511000	usd
CY2023Q1	gahr	Proceedsfromredeemablenoncontrollinginterest Proceedsfromredeemablenoncontrollinginterest	0	usd
CY2022Q1	gahr	Proceedsfromredeemablenoncontrollinginterest Proceedsfromredeemablenoncontrollinginterest	173000	usd
CY2023Q1	gahr	Paymentsto Redeemable Noncontrolling Interest PaymentstoRedeemableNoncontrollingInterest	560000	usd
CY2022Q1	gahr	Paymentsto Redeemable Noncontrolling Interest PaymentstoRedeemableNoncontrollingInterest	695000	usd
CY2023Q1	gahr	Repurchaseofstockwarrantsandredeemablenoncontrollinginterests Repurchaseofstockwarrantsandredeemablenoncontrollinginterests	15803000	usd
CY2022Q1	gahr	Repurchaseofstockwarrantsandredeemablenoncontrollinginterests Repurchaseofstockwarrantsandredeemablenoncontrollinginterests	0	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3000	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9000	usd
CY2023Q1	gahr	Increase Decrease In Security Deposits Financing Activities IncreaseDecreaseInSecurityDepositsFinancingActivities	-145000	usd
CY2022Q1	gahr	Increase Decrease In Security Deposits Financing Activities IncreaseDecreaseInSecurityDepositsFinancingActivities	-199000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-14300000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1307000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-23757000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6314000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111906000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125486000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88229000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	119170000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65052000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81597000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	46854000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	43889000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111906000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125486000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41346000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75115000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	46883000	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	44055000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88229000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	119170000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	37424000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	18916000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	383000	usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	191000	usd
CY2023Q1	gahr	Developments And Capital Expenditures Incurred But Not Yet Paid DevelopmentsAndCapitalExpendituresIncurredButNotYetPaid	26102000	usd
CY2022Q1	gahr	Developments And Capital Expenditures Incurred But Not Yet Paid DevelopmentsAndCapitalExpendituresIncurredButNotYetPaid	14750000	usd
CY2023Q1	gahr	Tenant Improvement Overage TenantImprovementOverage	0	usd
CY2022Q1	gahr	Tenant Improvement Overage TenantImprovementOverage	223000	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022Q1	us-gaap	Stock Issued1 StockIssued1	11304000	usd
CY2023Q1	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	16554000	usd
CY2022Q1	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	8794000	usd
CY2023Q1	gahr	Distributions Declared But Not Yet Paid To Limited Partnership Units DistributionsDeclaredButNotYetPaidToLimitedPartnershipUnits	875000	usd
CY2022Q1	gahr	Distributions Declared But Not Yet Paid To Limited Partnership Units DistributionsDeclaredButNotYetPaidToLimitedPartnershipUnits	467000	usd
CY2023Q1	gahr	Distributions Declared But Not Yet Paid To Restricted Stock Units DistributionsDeclaredButNotYetPaidToRestrictedStockUnits	68000	usd
CY2022Q1	gahr	Distributions Declared But Not Yet Paid To Restricted Stock Units DistributionsDeclaredButNotYetPaidToRestrictedStockUnits	0	usd
CY2023Q1	gahr	Accrued Offering Costs AccruedOfferingCosts	1255000	usd
CY2022Q1	gahr	Accrued Offering Costs AccruedOfferingCosts	0	usd
CY2023Q1	gahr	Noncash Or Part Noncash Acquisition And Disposals Accounts And Other Receivables Assumed NoncashOrPartNoncashAcquisitionAndDisposalsAccountsAndOtherReceivablesAssumed	-952000	usd
CY2022Q1	gahr	Noncash Or Part Noncash Acquisition And Disposals Accounts And Other Receivables Assumed NoncashOrPartNoncashAcquisitionAndDisposalsAccountsAndOtherReceivablesAssumed	-173000	usd
CY2023Q1	gahr	Noncashor Part Noncash Acquisitionsand Disposals Increase Decreasein Other Assets NoncashorPartNoncashAcquisitionsandDisposalsIncreaseDecreaseinOtherAssets	162000	usd
CY2022Q1	gahr	Noncashor Part Noncash Acquisitionsand Disposals Increase Decreasein Other Assets NoncashorPartNoncashAcquisitionsandDisposalsIncreaseDecreaseinOtherAssets	5023000	usd
CY2023Q1	gahr	Noncash Or Part Noncash Acquisition And Disposals Mortgage Loans Payable Assumed NoncashOrPartNoncashAcquisitionAndDisposalsMortgageLoansPayableAssumed	0	usd
CY2022Q1	gahr	Noncash Or Part Noncash Acquisition And Disposals Mortgage Loans Payable Assumed NoncashOrPartNoncashAcquisitionAndDisposalsMortgageLoansPayableAssumed	-12059000	usd
CY2023Q1	gahr	Noncash Or Part Noncash Acquisition And Disposals Payables Assumed NoncashOrPartNoncashAcquisitionAndDisposalsPayablesAssumed	548000	usd
CY2022Q1	gahr	Noncash Or Part Noncash Acquisition And Disposals Payables Assumed NoncashOrPartNoncashAcquisitionAndDisposalsPayablesAssumed	-21000	usd
CY2023Q1	gahr	Noncash Or Part Noncash Acquisition And Disposals Financing Obligations Assumed NoncashOrPartNoncashAcquisitionAndDisposalsFinancingObligationsAssumed	12000	usd
CY2022Q1	gahr	Noncash Or Part Noncash Acquisition And Disposals Financing Obligations Assumed NoncashOrPartNoncashAcquisitionAndDisposalsFinancingObligationsAssumed	56000	usd
CY2023Q1	gahr	Noncash Or Part Noncash Acquisition And Disposals Security Deposits Prepaid Rent And Other Liabilities Assumed NoncashOrPartNoncashAcquisitionAndDisposalsSecurityDepositsPrepaidRentAndOtherLiabilitiesAssumed	312000	usd
CY2022Q1	gahr	Noncash Or Part Noncash Acquisition And Disposals Security Deposits Prepaid Rent And Other Liabilities Assumed NoncashOrPartNoncashAcquisitionAndDisposalsSecurityDepositsPrepaidRentAndOtherLiabilitiesAssumed	7746000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Organization and Description of Business</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview and Background</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Healthcare REIT, Inc., a Maryland corporation, is a self-managed real estate investment trust, or REIT, that owns a diversified portfolio of clinical healthcare real estate properties, focusing primarily on medical office buildings, or MOBs, senior housing facilities, skilled nursing facilities, or SNFs, hospitals and other healthcare-related facilities. We also operate healthcare-related facilities utilizing the structure permitted by the REIT Investment Diversification and Empowerment Act of 2007, which is commonly referred to as a “RIDEA” structure (the provisions of the Internal Revenue Code of 1986, as amended, or the Code, authorizing the RIDEA structure were enacted as part of the Housing and Economic Recovery Act of 2008). Our healthcare facilities operated under a RIDEA structure include our senior housing operating properties, or SHOP, and our integrated senior health campuses. We have originated and acquired secured loans and may also originate and acquire other real estate-related investments on an infrequent and opportunistic basis. We generally seek investments that produce current income; however, we have selectively developed, and may continue to selectively develop, healthcare real estate properties. We have elected to be taxed as a REIT for U.S. federal income tax purposes. We believe that we have been organized and operated, and we intend to continue to operate, in conformity with the requirements for qualification and taxation as a REIT under the Code. </span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, Griffin-American Healthcare REIT III, Inc., or GAHR III, merged with and into a wholly owned subsidiary, or Merger Sub, of Griffin-American Healthcare REIT IV, Inc., or GAHR IV, with Merger Sub being the surviving company, which we refer to as the REIT Merger, and our operating partnership, Griffin-American Healthcare REIT IV Holdings, LP, merged with and into Griffin-American Healthcare REIT III Holdings, LP, or the Surviving Partnership, with the Surviving Partnership being the surviving entity, which we refer to as the Partnership Merger and, together with the REIT Merger, the Merger. Following the Merger on October 1, 2021, our company, or the Combined Company, was renamed American Healthcare REIT, Inc. and the Surviving Partnership was renamed American Healthcare REIT Holdings, LP, or our operating partnership.</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on October 1, 2021, immediately prior to the consummation of the Merger, and pursuant to a contribution and exchange agreement dated June 23, 2021, GAHR III acquired a newly formed entity, American Healthcare Opps Holdings, LLC, or NewCo, which we refer to as the AHI Acquisition. Following the Merger and the AHI Acquisition, our company became self-managed.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Partnership</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct substantially all of our operations through our operating partnership and we are the sole general partner of our operating partnership. As of both March 31, 2023 and December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we owned 95.0% of the partnership units, or OP units, in our operating partnership, and the remaining 5.0% limited OP units, were owned by AHI Group Holdings, LLC, which is owned and controlled by Jeffrey T. Hanson, the non-executive Chairman of our board of directors, or our board, Danny Prosky, our Chief Executive Officer and President, and Mathieu B. Streiff, one of our directors, or collectively, the AHI Principals; Platform Healthcare Investor TII, LLC; Flaherty Trust; and a wholly owned subsidiary of Griffin Capital Company, LLC, or collectively, the NewCo Sellers. See Note 12, Redeemable Noncontrolling Interests, and Note 13, Equity — Noncontrolling Interests in Total Equity, for a further discussion of the ownership in our operating partnership.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, after taking into consideration the impact of the Merger and the reverse stock split as discussed in Note 2, Summary of Significant Accounting Policies, we had issued 65,445,557 shares for a total of $2,737,716,000 of common stock since February 26, 2014 in our initial public offerings and our distribution reinvestment plan, or DRIP, offerings (includes historical offering amounts sold by GAHR III and GAHR IV prior to the Merger). </span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2022, we filed with the United States Securities and Exchange Commission, or the SEC, a Registration Statement on Form S-11 (File No. 333-267464), with respect to a proposed public offering by us of our shares of common stock in conjunction with a contemplated listing of our common stock on the New York Stock Exchange, or the Proposed Listing. Such registration statement and contemplated listing are not yet effective.</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13, Equity — Common Stock, and Note 13, Equity — Distribution Reinvestment Plan, for a further discussion of our public offerings. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Real Estate Investments Portfolio</span></div><div style="margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate through six reportable business segments: integrated senior health campuses, MOBs, SHOP, SNFs, senior housing — leased and hospitals. As of March 31, 2023, we owned and/or operated 314 buildings and integrated senior health campuses, including completed development and expansion projects, or approximately 19,956,000 square feet of gross leasable area, or GLA, for an aggregate contract purchase price of $4,626,119,000. In addition, as of March 31, 2023, we also owned a real estate-related debt investment purchased for $60,429,000.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 </span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our residents, tenants, operating partners and managers, our industry and the U.S. economy have been adversely affected by the impact of the COVID-19 pandemic. While the COVID-19 pandemic has subsided from its peaks, the timing and extent of the economic recovery from the COVID-19 pandemic is dependent upon many factors, including the emergence and severity of new COVID-19 variants, the effectiveness of vaccines, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, the overall pace of recovery, among others. As the lasting economic effects of the responses to the COVID-19 pandemic, such as inflation and labor market challenges, are still impacting the healthcare system to a certain extent, such effects continue to present challenges for us as an owner and operator of healthcare facilities, making it difficult to ascertain the long-term impact the COVID-19 pandemic will have on real estate markets in which we own and/or operate properties and our portfolio of investments. </span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have evaluated such economic impacts of the COVID-19 pandemic on our business thus far and incorporated information concerning such impacts into our assessments of liquidity, impairment and collectability from tenants and residents as of March 31, 2023. We will continue to monitor such impacts and will adjust our estimates and assumptions based on the best available information.</span></div>
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	6	segment
CY2023Q1	gahr	Number Of Buildings And Integrated Senior Health Campuses Owned And Or Operated NumberOfBuildingsAndIntegratedSeniorHealthCampusesOwnedAndOrOperated	314	campus
CY2023Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	19956000	sqft
	gahr	Acquisition Aggregated Cost Of Acquired Properties Purchase Price Netof Disposals AcquisitionAggregatedCostOfAcquiredPropertiesPurchasePriceNetofDisposals	4626119000	usd
	gahr	Acquisition Aggregated Cost Of Acquired Real Estate Related Investment Purchase Price AcquisitionAggregatedCostOfAcquiredRealEstateRelatedInvestmentPurchasePrice	60429000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14071000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities, at the date of our condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include, but are not limited to, the initial and recurring valuation of certain assets acquired and liabilities assumed through property acquisitions, including through business combinations, goodwill and its impairment, revenues and grant income, allowance for credit losses, impairment of long-lived and intangible assets and contingencies. These estimates are made and evaluated on an on-going basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates, perhaps in material adverse ways, and those estimates could be different under different assumptions or conditions.</span></div>
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts	<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Resident and Tenant Receivables and Allowances </span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Resident receivables, which are related to resident fees and services revenue, are carried net of an allowance for credit losses. An allowance is maintained for estimated losses resulting from the inability of residents and payors to meet the contractual obligations under their lease or service agreements. Substantially all of such allowances are recorded as direct reductions of resident fees and services revenue as contractual adjustments provided to third-party payors or implicit price concessions in our accompanying condensed consolidated statements of operations and comprehensive loss. Our determination of the adequacy of these allowances is based primarily upon evaluations of historical loss experience, the residents’ financial condition, security deposits, cash collection patterns by payor and by state, current economic conditions, future expectations in estimating credit losses and other relevant factors. Tenant receivables, which are related to real estate revenue, and unbilled deferred rent receivables are reduced for amounts where collectability is not probable, which are recognized as direct reductions of real estate revenue in our accompanying condensed consolidated statements of operations and comprehensive loss.</span></div>
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14391000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	4037000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	5223000	usd
CY2023Q1	gahr	Accounts Receivable Allowancefor Credit Loss Period Increase Decreasefrom Collectionsor Adjustments AccountsReceivableAllowanceforCreditLossPeriodIncreaseDecreasefromCollectionsorAdjustments	-1827000	usd
CY2022Q1	gahr	Accounts Receivable Allowancefor Credit Loss Period Increase Decreasefrom Collectionsor Adjustments AccountsReceivableAllowanceforCreditLossPeriodIncreaseDecreasefromCollectionsorAdjustments	-2099000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1890000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1630000	usd
CY2023Q1	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	41602000	usd
CY2022Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	39893000	usd
CY2023Q1	gahr	Reimbursement Of Payroll Related Costs To Managers ReimbursementOfPayrollRelatedCostsToManagers	39718000	usd
CY2022Q4	gahr	Reimbursement Of Payroll Related Costs To Managers ReimbursementOfPayrollRelatedCostsToManagers	38624000	usd
CY2023Q1	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	26168000	usd
CY2022Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	24926000	usd
CY2023Q1	gahr	Accrued Developments And Capital Expenditures AccruedDevelopmentsAndCapitalExpenditures	26102000	usd
CY2022Q4	gahr	Accrued Developments And Capital Expenditures AccruedDevelopmentsAndCapitalExpenditures	30211000	usd
CY2023Q1	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	16554000	usd
CY2022Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	26484000	usd
CY2023Q1	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	4257806000	usd
CY2022Q4	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	4236447000	usd
CY2023Q1	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	689689000	usd
CY2022Q4	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	654838000	usd
CY2023Q1	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	3568117000	usd
CY2022Q4	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	3581609000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	35899000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	34422000	usd
CY2023Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	83955000	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	83000000	usd
CY2023Q1	gahr	Heldto Maturity Debt Securities Unamortizedclosingcosts HeldtoMaturityDebtSecuritiesUnamortizedclosingcosts	701000	usd
CY2022	gahr	Heldto Maturity Debt Securities Unamortizedclosingcosts HeldtoMaturityDebtSecuritiesUnamortizedclosingcosts	767000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1020000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	980000	usd
CY2023Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	65000	usd
CY2022Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	56000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	219279000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	236283000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17071000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8239000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y6M
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y8M12D
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	20289000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	12861000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10037000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8867000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8230000	usd
CY2023Q1	gahr	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	30529000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	90813000	usd
CY2023Q1	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	6503000	usd
CY2023Q1	gahr	Capitalizeddeferredfinancingcostsformortgages Capitalizeddeferredfinancingcostsformortgages	142000	usd
CY2023Q1	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	47911000	usd
CY2022Q4	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	46867000	usd
CY2023Q1	gahr	Prepaid Expense Deposits Other Assets And Deferred Tax Assets PrepaidExpenseDepositsOtherAssetsAndDeferredTaxAssets	31219000	usd
CY2022Q4	gahr	Prepaid Expense Deposits Other Assets And Deferred Tax Assets PrepaidExpenseDepositsOtherAssetsAndDeferredTaxAssets	25866000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	19053000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	19775000	usd
CY2023Q1	us-gaap	Deferred Costs Leasing Accumulated Amortization DeferredCostsLeasingAccumulatedAmortization	6636000	usd
CY2022Q4	us-gaap	Deferred Costs Leasing Accumulated Amortization DeferredCostsLeasingAccumulatedAmortization	6260000	usd
CY2023Q1	us-gaap	Deferred Costs Leasing Net DeferredCostsLeasingNet	18384000	usd
CY2022Q4	us-gaap	Deferred Costs Leasing Net DeferredCostsLeasingNet	19217000	usd
CY2023Q1	us-gaap	Equity Method Investments EquityMethodInvestments	15399000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	9580000	usd
CY2022Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	5704000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3795000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	4334000	usd
CY2023Q1	gahr	Accumulated Amortization Lease Inducements AccumulatedAmortizationLeaseInducements	2281000	usd
CY2022Q4	gahr	Accumulated Amortization Lease Inducements AccumulatedAmortizationLeaseInducements	2193000	usd
CY2023Q1	gahr	Lease Inducements Weighted Average Remaining Life LeaseInducementsWeightedAverageRemainingLife	P7Y8M12D
CY2022	gahr	Lease Inducements Weighted Average Remaining Life LeaseInducementsWeightedAverageRemainingLife	P7Y10M24D
CY2023Q1	us-gaap	Incentive To Lessee IncentiveToLessee	2719000	usd
CY2022Q4	us-gaap	Incentive To Lessee IncentiveToLessee	2807000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	138480000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	128446000	usd
CY2022Q1	gahr	Amortizationof Deferred Lease Inducements AmortizationofDeferredLeaseInducements	88000	usd
CY2023Q1	gahr	Amortizationof Deferred Lease Inducements AmortizationofDeferredLeaseInducements	88000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1257057000	usd
CY2023Q1	us-gaap	Secured Debt SecuredDebt	1233745000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1254479000	usd
CY2022Q4	us-gaap	Secured Debt SecuredDebt	1229847000	usd
CY2023Q1	gahr	Number Of Fixed Rate Mortgage Loans Payable NumberOfFixedRateMortgageLoansPayable	68	mortgageloan
CY2023Q1	gahr	Number Of Variable Rate Mortgage Loans Payable NumberOfVariableRateMortgageLoansPayable	12	mortgageloan
CY2022Q4	gahr	Number Of Fixed Rate Mortgage Loans Payable NumberOfFixedRateMortgageLoansPayable	68	mortgageloan
CY2022Q4	gahr	Number Of Variable Rate Mortgage Loans Payable NumberOfVariableRateMortgageLoansPayable	11	mortgageloan
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1257057000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1254479000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	215000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	237000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	15117000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	16024000	usd
CY2023Q1	us-gaap	Secured Debt SecuredDebt	1233745000	usd
CY2022Q4	us-gaap	Secured Debt SecuredDebt	1229847000	usd
CY2022Q4	us-gaap	Secured Debt SecuredDebt	1229847000	usd
CY2021Q4	us-gaap	Secured Debt SecuredDebt	1095594000	usd
CY2023Q1	gahr	Proceeds From Mortgage Loans ProceedsFromMortgageLoans	7700000	usd
CY2022Q1	gahr	Proceeds From Mortgage Loans ProceedsFromMortgageLoans	88659000	usd
CY2023Q1	gahr	Amortizationofdeferredfinancingcostsrelatedtomortgage Amortizationofdeferredfinancingcostsrelatedtomortgage	577000	usd
CY2022Q1	gahr	Amortizationofdeferredfinancingcostsrelatedtomortgage Amortizationofdeferredfinancingcostsrelatedtomortgage	2078000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	885000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-17000	usd
CY2023Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	5122000	usd
CY2022Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	4538000	usd
CY2023Q1	gahr	Early Payoff Of Mortgage Payable EarlyPayoffOfMortgagePayable	0	usd
CY2022Q1	gahr	Early Payoff Of Mortgage Payable EarlyPayoffOfMortgagePayable	78437000	usd
CY2023Q1	gahr	Redeemable Noncontrolling Interest Distributions RedeemableNoncontrollingInterestDistributions	454000	usd
CY2022Q1	gahr	Capitalizeddeferredfinancingcostsformortgages Capitalizeddeferredfinancingcostsformortgages	333000	usd
CY2023Q1	us-gaap	Secured Debt SecuredDebt	1233745000	usd
CY2022Q1	us-gaap	Secured Debt SecuredDebt	1103006000	usd
CY2022Q1	gahr	Number Of Debt Instruments Extinguished NumberOfDebtInstrumentsExtinguished	8	mortgageloan
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	128240000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	278056000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	165544000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	155159000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	34413000	usd
CY2023Q1	gahr	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	495645000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1257057000	usd
CY2022Q1	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	3161000	usd
CY2023Q1	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-195000	usd
CY2022Q1	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	500000	usd
CY2023Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses Remainder Of Fiscal Year FiniteLivedIntangibleLiabilitiesAmortizationExpensesRemainderOfFiscalYear	1188000	usd
CY2023Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Two FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearTwo	1475000	usd
CY2023Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Three FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearThree	1347000	usd
CY2023Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Four FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearFour	1198000	usd
CY2023Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Five FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearFive	1162000	usd
CY2023Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses After Year Five FiniteLivedIntangibleLiabilitiesAmortizationExpensesAfterYearFive	4059000	usd
CY2023Q1	gahr	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	10429000	usd
CY2023Q1	gahr	Limited Liability Company Llc Or Limited Partnership Lp Managing Member Or General Partner Ownership Interest With Redemption Features Outstanding LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterestWithRedemptionFeaturesOutstanding	0.010
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	81598000	usd
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	72725000	usd
CY2023Q1	gahr	Additional Redeemable Noncontrolling Interests AdditionalRedeemableNoncontrollingInterests	0	usd
CY2022Q1	gahr	Additional Redeemable Noncontrolling Interests AdditionalRedeemableNoncontrollingInterests	173000	usd
CY2023Q1	gahr	Reclassificationof Noncontrolling Interest ReclassificationofNoncontrollingInterest	-21000	usd
CY2022Q1	gahr	Reclassificationof Noncontrolling Interest ReclassificationofNoncontrollingInterest	-21000	usd
CY2022Q1	gahr	Redeemable Noncontrolling Interest Distributions RedeemableNoncontrollingInterestDistributions	695000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	15870000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	0	usd
CY2023Q1	gahr	Adjustments To Additional Paid In Capital Adjustment To Redeemable Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalAdjustmentToRedeemableNoncontrollingInterests	-5043000	usd
CY2022Q1	gahr	Adjustments To Additional Paid In Capital Adjustment To Redeemable Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalAdjustmentToRedeemableNoncontrollingInterests	2856000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-368000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	187000	usd
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	59884000	usd
CY2022Q1	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	75267000	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Subscribed But Unissued Value PreferredStockSharesSubscribedButUnissuedValue	125000	usd
CY2023Q1	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.125	rate
CY2023Q1	gahr	Operating Partnership Units Outstanding Presented In Total Equity Percent OperatingPartnershipUnitsOutstandingPresentedInTotalEquityPercent	0.040
CY2022Q4	gahr	Operating Partnership Units Outstanding Presented In Total Equity Percent OperatingPartnershipUnitsOutstandingPresentedInTotalEquityPercent	0.040
CY2023Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	83955000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	93248000	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	83000000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	93230000	usd
CY2023Q1	us-gaap	Secured Debt SecuredDebt	1233745000	usd
CY2023Q1	us-gaap	Loans Payable Fair Value Disclosure LoansPayableFairValueDisclosure	1097904000	usd
CY2022Q4	us-gaap	Secured Debt SecuredDebt	1229847000	usd
CY2022Q4	us-gaap	Loans Payable Fair Value Disclosure LoansPayableFairValueDisclosure	1091667000	usd
CY2023Q1	gahr	Linesofcreditandtermloannet Linesofcreditandtermloannet	1309427000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	1315836000	usd
CY2022Q4	gahr	Linesofcreditandtermloannet Linesofcreditandtermloannet	1277460000	usd
CY2022Q4	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	1285205000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	303000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	312000	usd
CY2023Q1	gahr	Operating Lease Revenue OperatingLeaseRevenue	42303000	usd
CY2022Q1	gahr	Operating Lease Revenue OperatingLeaseRevenue	50731000	usd
CY2023Q1	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	10040000	usd
CY2022Q1	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	10413000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	115063000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	146081000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	132908000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	121949000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	115863000	usd
CY2023Q1	gahr	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	580286000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	1212150000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	11923000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	6356000	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	91000	usd
CY2023Q1	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	43596000	usd
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	74000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	156000	usd
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	147000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	12161000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	6595000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y9M18D
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0570
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0569
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0761
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0766
CY2023Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	91000	usd
CY2022Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	74000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	16000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	13000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1155000	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	29017000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	37779000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	37197000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	37255000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	37890000	usd
CY2023Q1	gahr	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	229083000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	408221000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	139634000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	268587000	usd
CY2023Q1	gahr	Revenuesand Government Grant Income From Cares Act RevenuesandGovernmentGrantIncomeFromCARESAct	452226000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	370146000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	53000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	76000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	31000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q1	gahr	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	160000	usd
CY2023Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	14000	usd
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	146000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	6	segment
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	408630000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	15195000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	66885000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13053000	usd
CY2023Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	332000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	44670000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	39011000	usd
CY2023Q1	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-195000	usd
CY2023Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	-132000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-306000	usd
CY2023Q1	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	726000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1008000	usd
CY2023Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1608000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-36302000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27472000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	143000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-27615000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	318974000	usd
CY2022Q1	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	51943000	usd
CY2022Q1	gahr	Government Grant Income From Cares Act GovernmentGrantIncomeFromCARESAct	5214000	usd
CY2022Q1	gahr	Revenuesand Government Grant Income From Cares Act RevenuesandGovernmentGrantIncomeFromCARESAct	376131000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	287160000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	15287000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	73684000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11119000	usd
CY2022Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	173000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42311000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	23325000	usd
CY2022Q1	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	500000	usd
CY2022Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	756000	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1386000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1387000	usd
CY2022Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1260000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20810000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-729000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	168000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-897000	usd
CY2023Q1	us-gaap	Assets Assets	4747681000	usd
CY2022Q4	us-gaap	Assets Assets	4786698000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	231611000	usd
CY2023Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	3331000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	234942000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	209898000	usd
CY2022Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	1827000	usd
CY2022Q1	us-gaap	Goodwill Goodwill	211725000	usd
CY2023Q1	gahr	Revenuesand Government Grant Income From Cares Act RevenuesandGovernmentGrantIncomeFromCARESAct	452226000	usd
CY2022Q1	gahr	Revenuesand Government Grant Income From Cares Act RevenuesandGovernmentGrantIncomeFromCARESAct	376131000	usd
CY2023Q1	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	3568117000	usd
CY2022Q4	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	3581609000	usd
CY2023Q1	gahr	Concentration Risk Number Of States That Generated At Least Ten Percent Of Annualized Base Rent ConcentrationRiskNumberOfStatesThatGeneratedAtLeastTenPercentOfAnnualizedBaseRent	1	state
CY2023Q1	gahr	Minimum Percent Share Of Each State Annualized Base Rent That Company Owned MinimumPercentShareOfEachStateAnnualizedBaseRentThatCompanyOwned	0.100
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	6	segment
CY2023Q1	gahr	Number Of Tenants With More Than Ten Percent Of Annual Base Rent NumberOfTenantsWithMoreThanTenPercentOfAnnualBaseRent	0	tenant
CY2023Q1	gahr	Minimum Percent Share Of Annualized Base Rent Accounted By Tenants MinimumPercentShareOfAnnualizedBaseRentAccountedByTenants	0.100
CY2023Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	926000	usd
CY2022Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	1490000	usd

Files In Submission

Name	View Source	Status
0001632970-23-000058-index-headers.html	Edgar Link	pending
0001632970-23-000058-index.html	Edgar Link	pending
0001632970-23-000058.txt	Edgar Link	pending
0001632970-23-000058-xbrl.zip	Edgar Link	pending
ex311-2023xq110xqahr.htm	Edgar Link	pending
ex312-2023xq110xqahr.htm	Edgar Link	pending
ex321-2023xq110xqahr.htm	Edgar Link	pending
ex322-2023xq110xqahr.htm	Edgar Link	pending
exh102trilogyfourthamend.htm	Edgar Link	pending
exh102trilogyfourthamend001.jpg	Edgar Link	pending
exh102trilogyfourthamend002.jpg	Edgar Link	pending
exh102trilogyfourthamend003.jpg	Edgar Link	pending
exh102trilogyfourthamend004.jpg	Edgar Link	pending
exh102trilogyfourthamend005.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
gahr-20230331.htm	Edgar Link	pending
gahr-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
gahr-20230331_def.xml	Edgar Link	unprocessable
gahr-20230331_lab.xml	Edgar Link	unprocessable
gahr-20230331_pre.xml	Edgar Link	unprocessable
gahr-20230331_htm.xml	Edgar Link	completed
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
gahr-20230331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AHR
American Healthcare REIT, Inc. Stock $ahr

2023 Q1 Form 10-Q Financial Statement

#000163297023000058 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AHR American Healthcare REIT, Inc. Stock $ahr

2023 Q1 Form 10-Q Financial Statement

#000163297023000058 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AHR
American Healthcare REIT, Inc. Stock $ahr